Pfizer Vaccine apparently effective for people suffering from severe diseases

Pfizer Inc (NYSE: PFE) and BioNTech SE - ADR (Nasdaq: BNTX) are impressed with their COVID-19 vaccine after studies prove its effectiveness. The vaccine creates hope in those struggling with chronic diseases such as heart disease and diabetes. The Israeli health care provider screened nearly 1.4 million people and hopes many countries around the world would benefit from the vaccine. The need to vaccinate citizens is inevitable and most governments have supported vaccination programs. Those at risk continue to receive special attention under the guidelines of health care providers and governments. The Covid-19 pandemic is deadly when you consider that it has already killed around 3.1 million people. The study by the Clalit Research Institute has provided details about the effectiveness of the vaccine. The first result was for people struggling with heart disease or chronic kidney disease and showed an effectiveness rate of 80%. The second result was for people with type 2 diabetes and represented a figure of 86%. The result for cerebrovascular disease was 75% effectiveness, and immunodeficiency was the last result that was given. It was 84% ​​effectiveness. Some of the people involved in the vaccination struggled with more than three or more chronic illnesses. The study outlined some of the risk factors and the percent effectiveness of the vaccine. Conditions included chronic lung disease, neurological disease, chronic kidney disease, heart disease, obesity, pregnancy, and smoking. The vaccine was 88% effective in symptomatic infections. The group, consisting of type 2 diabetes, cerebrovascular and heart diseases, enjoyed greater effectiveness, which was 90%. In the group with people struggling with immunodeficiency, it was 100%. The digitized Israeli health system provided excellent support for the vaccination program. The goal was to speed up the exercise to make sure more people benefit, with more attention paid to the weak. Researchers have reviewed the vaccine's potency and shared their perspectives. The researchers remain somewhat optimistic about the vaccine. They think the vaccine will be effective in people who get infections after vaccination. Harvard and the University of Michigan are the other parties that ran the test. It was on Thursday that the two published their results in the New England Journal of Medicine.